Table 2.
Antigen-wise doses scheduled by the gold standard (World Health Organization [WHO]–recommended Expanded Programme on Immunization [EPI] schedule)a, immunization decision support system (iDSS), and vaccinator for Pakistan and Bangladesh sites.
| Vaccines | Pakistan (n=13,036) | Bangladesh (n=4920) | Total (n=17,956)b | ||||||||||||||
|
|
Due as per gold standard, n | Due as per iDSS, n (%) | Vaccinated by vaccinator, n (%) | Due as per gold standard, n | Due as per iDSS, n (%) | Vaccinated by vaccinator, n (%) | Due as per gold standard, n | Due as per iDSS, n (%) | Vaccinated by vaccinator, n (%) | ||||||||
|
|
Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | No | Yes | Yes | No | Yes | No | ||
| BCGc | 1505 | 1505 (100) | N/Ad | 1477 (98.1) | 28 (1.9) | 372 | 372 (100) | N/A | 369 (99.2) | 3 (0.8) | 1877 | 1877 (100) | N/A | 1846 (98.3) | 31 (1.7) | ||
| OPV-0e | 1212 | 1212 (100) | N/A | 1210 (99.8) | 2 (0.2) | N/A | N/A | N/A | N/A | N/A | 1212 | 1212 (100) | N/A | 1210 (99.8) | 2 (0.2) | ||
| Penta-1f | 924 | 923 (99.8) | 1 (0.2) | 898 (97.2) | 26 (2.8) | 425 | 425 (100) | N/A | 419 (98.6) | 6 (1.4) | 1349 | 1348 (99.9) | 1 (0.1) | 1317 (97.6) | 32 (2.4) | ||
| OPV-1 | 924 | 923 (99.8) | 1 (0.2) | 896 (97) | 28 (3) | 424 | 424 (100) | N/A | 420 (99.1) | 4 (0.9) | 1348 | 1347 (99.9) | 1 (0.1) | 1316 (97.6) | 32 (2.4) | ||
| PCV-1g | 924 | 923 (99.8) | 1 (0.2) | 898 (97.2) | 26 (2.8) | 423 | 423 (100) | N/A | 419 (99.1) | 4 (0.9) | 1347 | 1346 (99.9) | 1 (0.1) | 1317 (97.8) | 30 (2.2) | ||
| Rota-1h | 924 | 923 (99.8) | 1 (0.2) | 898 (97.2) | 26 (2.8) | N/A | N/A | N/A | N/A | N/A | 924 | 923 (99.9) | 1 (0.1) | 898 (97.2) | 26 (2.8) | ||
| IPV-1i | N/A | N/A | N/A | N/A | N/A | 425 | 425 (100) | N/A | 420 (98.8) | 5 (1.2) | 425 | 425 (100) | N/A | 420 (98.8) | 5 (1.2) | ||
| Penta-2 | 786 | 785 (99.8) | 1 (0.2) | 786 (100) | N/A | 347 | 347 (100) | N/A | 347 (100) | N/A | 1133 | 1132 (99.9) | 1 (0.1) | 1133 (100) | N/A | ||
| OPV-2 | 785 | 784 (99.8) | 1 (0.2) | 785 (100) | N/A | 347 | 347 (100) | N/A | 347 (100) | N/A | 1132 | 1131 (99.9) | 1 (0.1) | 1132 (100) | N/A | ||
| PCV-2 | 785 | 784 (99.8) | 1 (0.2) | 785 (100) | N/A | 346 | 346 (100) | N/A | 346 (100) | N/A | 1131 | 1130 (99.9) | 1 (0.1) | 1131 (100) | N/A | ||
| Rota-2 | 784 | 783 (99.8) | 1 (0.2) | 784 (100) | N/A | N/A | N/A | N/A | N/A | N/A | 784 | 783 (99.9) | 1 (0.1) | 784 (100) | N/A | ||
| Penta-3 | 635 | 634 (99.8) | 1 (0.2) | 635 (100) | N/A | 354 | 354 (100) | N/A | 352 (99.4) | 2 (0.6) | 989 | 988 (99.9) | 1 (0.1) | 987 (99.8) | 2 (0.2) | ||
| OPV-3 | 637 | 636 (99.8) | 1 (0.2) | 635 (99.7) | 2 (0.3) | 354 | 354 (100) | N/A | 353 (99.7) | 1 (0.3) | 991 | 990 (99.9) | 1 (0.1) | 988 (99.7) | 3 (0.3) | ||
| PCV-3 | 637 | 636 (99.8) | 1 (0.2) | 635 (99.7) | 2 (0.3) | 354 | 354 (100) | N/A | 353 (99.7) | 1 (0.3) | 991 | 990 (99.9) | 1 (0.1) | 988 (99.7) | 3 (0.3) | ||
| IPV-2 | 985 | 982 (99.7) | 3 (0.3) | 653 (66.3) | 332 (33.7) | 406 | 406 (100) | N/A | 355 (87.4) | 51 (12.6) | 1391 | 1388 (99.8) | 3 (0.2) | 1008 (72.5) | 383 (27.5) | ||
| M-1j,k | 383 | 380 (99.2) | 3 (0.8) | 362 (94.5) | 21 (5.5) | 144 | 144 (100) | N/A | 137 (95.1) | 7 (4.9) | 527 | 524 (99.4) | 3 (0.6) | 499 (94.7) | 28 (5.3) | ||
| M-2k | 209 | 202 (96.7) | 7 (3.3) | 208 (99.5) | 1 (0.5) | 201 | 196 (97.5) | 5 (2.4) | 196 (97.5) | 5 (2.5) | 410 | 398 (97.1) | 12 (2.9) | 404 (98.5) | 6 (1.5) | ||
| Total | 13039 | 13015 (99.8) | 24 (0.2) | 12545 (96.2) | 494 (3.8) | 4922 | 4917 (99.9) | 5 (0.1) | 4833 (98.2) | 89 (1.8) | 17961 | 17932 (99.8) | 29 (0.2) | 17378 (96.8) | 583 (3.2) | ||
aWHO-recommended EPI schedule constructed by a vaccine expert, using the following criteria: BCG at ≤1-year age; OPV-0 at ≤28 days; Penta-1, OPV-1, PCV-1, Rota-1, and IPV-1 at ≥6 weeks; Penta-2, OPV-2, PCV-2, and Rota-2 at ≥10 weeks and >28 days after vaccination with Penta-1, PCV-1, OPV-1, and Rota-1; Penta-3, OPV-3, and PCV-3 at ≥4 weeks age and >28 days after vaccination with Penta-2, PCV-2, and OPV-2; IPV-2 at ≥14 weeks age (for Bangladesh, >28 days after IPV-1); measles-1 at 9 months; measles-2 at 15 months and >28 days after measles-1 vaccine (source: WHO-2020, Expanded Program on Immunization, Pakistan; WHO-2019, Fact sheet Bangladesh).
bn is the number of doses due for each antigen for the 6241 immunization visits recorded for 4613 children from both Pakistan and Bangladesh sites.
cBCG: bacille Calmette-Guérin.
dN/A: not applicable.
eOPV: oral polio vaccine.
fPenta: pentavalent vaccine.
gPCV: pneumococcal vaccine.
hRota: rotavirus vaccine.
iIPV: inactivated polio vaccine.
jM: measles vaccine.
kIn Bangladesh, measles-rubella combined vaccine is administered.